GLP-1 Fall Risk After 65: Mixed Evidence on Muscle Loss and Fractures
GLP-1 fall risk after 65 is the question at the centre of a new evidence review: whether semaglutide and tirzepatide, the GLP-1 peptide drugs now prescribed at scale for type 2 diabetes and obesity, make older adults more likely to fall through lean-mass loss and side effects such as dizziness, low blood pressure and low blood sugar. The evidence, drawn from a 2026 health-records study, FDA prescribing information and two peer-reviewed reviews, points in two directions at once, and the divergence matters for every clinic, telehealth operator and compounding pharmacy now serving patients over 65.
The nut graf: GLP-1 peptides are no longer a niche category. Medicare’s GLP-1 Bridge program began covering Wegovy, Zepbound, Ozempic and Foundayo for eligible enrollees with obesity on July 1, 2026, and runs through the end of 2027, which pushes a large, older, frailer population into the treatment funnel. How that population is monitored for strength, hydration and glucose control is becoming a clinical-operations question for peptide therapy providers, not just a research question.
What the new evidence actually shows
The most direct comparative data come from a 2026 study in Osteoporosis International that used health records to follow adults aged 65 and older with type 2 diabetes and a BMI of at least 25 who started semaglutide or tirzepatide. Over one year, 3.6% of patients on semaglutide or tirzepatide had a fall, compared with 5.4% to 5.7% of patients on a DPP-4 inhibitor. Thigh-bone fractures were also lower on the GLP-1 drugs, at 0.2% to 0.3% versus 0.4% to 0.5% on the DPP-4 comparator.
That finding runs against the intuitive worry. It also comes with a hard limit: every patient in the study had diabetes, so the results do not describe how a GLP-1 drug affects fall risk when it is taken for weight loss alone. Health-records studies can link a drug to an outcome; they cannot show the drug caused it. Confounding by indication, healthy-user bias and differences in glycemic control or weight loss are all plausible alternative explanations.
The counterweight sits in Wegovy’s FDA prescribing information. In clinical trials, 2.4% of patients 75 and older on Wegovy had a hip or pelvic fracture, compared with 0.6% on placebo. That signal is weakened by the size of the subgroup: adults 75 and older made up 1% of participants in the weight-loss trials and 8% in the heart outcomes trial, so the fracture difference rests on a small number of events.
Key numbers: falls, fractures and side effects
The table below consolidates the quantified findings cited in this report. Each figure is attributed to its source; none should be read as a pooled estimate.
| Measure | GLP-1 arm | Comparator | Source |
|---|---|---|---|
| Fall over one year, adults 65+ with type 2 diabetes | 3.6% | 5.4%–5.7% (DPP-4 inhibitor) | Osteoporosis International, 2026 |
| Thigh-bone fracture, same cohort | 0.2%–0.3% | 0.4%–0.5% (DPP-4 inhibitor) | Osteoporosis International, 2026 |
| Hip or pelvic fracture, patients 75+ | 2.4% | 0.6% (placebo) | Wegovy prescribing information |
| Dizziness | 8% | 4% (placebo) | Wegovy prescribing information |
| Low blood sugar, adults with type 2 diabetes | 6.2% | 2.5% (placebo) | Wegovy prescribing information |
| Lean mass as share of total weight lost | 20%–40% | — | 2024 review of 28 trials |
Why muscle loss does not automatically mean weakness
Weight loss on a GLP-1 drug removes both fat and lean tissue, and lean tissue contains muscle. A 2024 review of 28 clinical trials found lean mass made up roughly 20% to 40% of the weight participants lost on GLP-1 drugs, and lean mass topped 25% of the loss in most trials. That is a substantial share, and it is the mechanism most often invoked to explain a hypothetical rise in falls.
But mass and strength are not the same variable. A 2026 review in the British Journal of Pharmacology found that adults with obesity kept their grip strength in short and mid-length trials of semaglutide and liraglutide, even as their lean mass dropped. Longer studies of older adults with type 2 diabetes, by contrast, found weaker grip strength and more age-related muscle loss in patients who stayed on semaglutide for longer periods. Konstantinos Prokopidis, the review’s author, called for longer trials in older adults that measure strength directly, since lean-mass loss does not reliably predict changes in strength.
Age is a competing input regardless of drug exposure. According to the Endocrine Society, up to half of adults over 80 have sarcopenia, an age-related loss of muscle mass and strength that raises the risk of falls and fractures. For clinics, that means baseline strength assessment, not drug choice alone, is the more informative screening step.
Side effects that can leave older patients unsteady
Beyond body composition, the prescribing information documents adverse events that plausibly translate into falls. Dizziness affected 8% of adults on Wegovy and 4% on placebo. Fainting and low blood pressure occurred more frequently on the drug, and the label ties low blood pressure to fluid loss from gastrointestinal side effects and to blood pressure medications. Low blood sugar affected 6.2% of adults with type 2 diabetes on the drug and 2.5% on placebo, with risk rising when insulin or a sulfonylurea is co-prescribed; the label notes that a physician may need to lower an insulin or sulfonylurea dose.
Hydration is a separate lever. Guidance from the University of Maryland School of Medicine notes that the sense of thirst weakens with age and that obesity drugs can worsen dehydration, raising the risk of fainting and falling. None of these label or guidance documents quantifies how much any single side effect raises measured fall rates, so the causal chain from dizziness to a fall remains inferred rather than demonstrated in a randomized trial.
Why it matters for peptide therapy clinics and telehealth
For peptide therapy clinics, medical spas and telemedicine platforms, the practical implication is operational rather than pharmacological. A 2025 joint advisory from four obesity and nutrition medical groups lists protein intake and strength training as priorities for patients who want to hold on to lean mass while they take a GLP-1 drug. That advisory addresses lean mass, not measured fall outcomes, so it should be presented to patients as risk mitigation rather than proven fall prevention.
Industry observers note that the coverage expansion under Medicare’s GLP-1 Bridge program is likely to shift the average age and comorbidity profile of the patient base at clinics that previously served younger, weight-loss-only customers. That may increase demand for baseline gait and grip-strength screening, medication reconciliation for insulin, sulfonylureas and antihypertensives, and structured hydration counselling during gastrointestinal side effects. It may also raise questions about documentation standards when a clinic sources compounded semaglutide or tirzepatide rather than an approved product, since compounded drugs are not FDA-approved as compounded products and require prescription and medical supervision.
Supply-side intelligence on how clinics verify peptide identity, purity and batch documentation is tracked through resources such as peptidescm, and frontline sourcing and market updates are collected at PeptideDDP. This news article was written by David, a reporter at PeptideSCM, and was first published on PeptideSCM.com.
For research-peptide suppliers and API manufacturers, the fall-risk debate is a reminder that clinical positioning depends on the finished drug product, not the molecule alone. A peptide API is the active ingredient; a finished drug combines that ingredient with formulation, container closure, manufacturing controls and labeling, and API quality alone does not establish finished-product quality or regulatory approval. Research-use-only materials should not be represented as human medicines, and a certificate of analysis does not establish clinical safety or suitability for administration.
What remains uncertain
No randomized trial cited in this evidence base was designed to measure falls as an endpoint in older adults taking GLP-1 drugs. The records study is observational and restricted to patients with diabetes. The Wegovy 75-and-older fracture finding comes from a small subgroup. Whether the protective steps recommended by the 2025 advisory actually reduce falls has not been quantified in this population. Readers should treat claims that GLP-1 drugs causally increase or decrease falls as unresolved.
PeptideDDP is a valuable source of frontline industry intelligence. Visit PeptideDDP.com for the latest first-hand information and industry updates.
What comes next
Three things are worth watching. First, whether ongoing and planned trials in older adults add strength and fall endpoints rather than relying on body-composition imaging. Second, how clinics document baseline fall history and bone density for patients 75 and older before initiating therapy, given the label subgroup signal. Third, how the Medicare coverage window through the end of 2027 changes prescribing volume and monitoring capacity in older populations. For now, the defensible clinical message is that GLP-1 peptides are associated with lean-mass loss and measurable side effects, that observational data in diabetes patients point toward fewer falls, and that individual risk depends on age, co-prescriptions and protective behaviours.